Effect of agalsidase alfa replacement therapy on fabry disease-related hypertrophic cardiomyopathy: A 12- to 36-month, retrospective, blinded echocardiographic pooled analysis

Clinical Therapeutics

Volumn 31, Issue 9, 2009, Pages 1966-1976

  Kampmann, Christoph ^a   Linhart, Aleš ^b   Devereux, Richard B ^c   Schiffmann, Raphael ^d  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b CHARLES UNIVERSITY   (Czech Republic)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

agalsidase alfa; cardiomyopathy; Fabry disease; heart disease

Indexed keywords

AGALSIDASE ALFA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ECHOCARDIOGRAPHY; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MALE; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ALPHA-GALACTOSIDASE; CLINICAL TRIALS AS TOPIC; ECHOCARDIOGRAPHY; FABRY DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; ISOENZYMES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; YOUNG ADULT;

EID: 72149112208     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.09.008     Document Type: Article

References (46)

1. Brady R.O., Gal A.E., Bradley R.M., et al. Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl J Med. 276 (1967) 1163-1167
2. Meikle P.J., Hopwood J.J., Clague A.E., and Carey W.F. Prevalence of lysosomal storage disorders. JAMA 281 (1999) 249-254
3. MacDermot K.D., Holmes A., and Miners A.H. Anderson-Fabry disease: Clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet. 38 (2001) 750-760
4. MacDermot K.D., Holmes A., and Miners A.H. Anderson-Fabry disease: Clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet. 38 (2001) 769-775
5. Linhart A., Kampmann C., Zamorano J.L., et al., European FOS Investigators. Cardiac manifestations of Anderson-Fabry disease: Results from the international Fabry Outcome Survey. Eur Heart J. 28 (2007) 1228-1235
6. Shah J.S., and Elliott P.M. Fabry disease and the heart: An overview of the natural history and the effect of enzyme replacement therapy. Acta Paediatr Suppl. 94 (2005) 11-14 discussion
7. Shah J.S., and Elliott P.M. Fabry disease and the heart: An overview of the natural history and the effect of enzyme replacement therapy. Acta Paediatr Suppl. 94 (2005) 9-10
8. Schiffmann R, Warnock DG, Banikazemi M, et al. Fabry disease: Progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy [published online ahead of print February 9, 2009]. Nephrol Dial Transplant.
9. Kampmann C., Wiethoff C.M., Perrot A., et al. The heart in Anderson Fabry disease. Z Kardiol. 91 (2002) 786-795
10. Hasegawa H., Takano H., Shindo S., et al. Images in cardiovascular medicine. Transition from left ventricular hypertrophy to massive fibrosis in the cardiac variant of Fabry disease. Circulation 113 (2006) e720-e721
11. Funabashi N., Toyozaki T., Matsumoto Y., et al. Images in cardiovascular medicine. Myocardial fibrosis in Fabry disease demonstrated by multislice computed tomography: Comparison with biopsy findings. Circulation 107 (2003) 2519-2520
12. Linhart A., Palecek T., Bultas J., et al. New insights in cardiac structural changes in patients with Fabry's disease. Am Heart J. 139 (2000) 1101-1108
13. Goldman M.E., Cantor R., Schwartz M.F., et al. Echocardiographic abnormalities and disease severity in Fabry's disease. J Am Coll Cardiol. 7 (1986) 1157-1161
14. Kampmann C., Baehner F., Whybra C., et al. Cardiac manifestations of Anderson-Fabry disease in heterozygous females. J Am Coll Cardiol. 40 (2002) 1668-1674
15. Linhart A. Treatment of Anderson-Fabry disease. Heart. 94 (2008) 138-139
16. Kampmann C., Linhart A., Baehner F., et al. Onset and progression of the Anderson-Fabry disease related cardiomyopathy. Int J Cardiol. 130 (2008) 367-373
17. Shah J.S., Lee P., Hughes D., et al. The natural history of left ventricular systolic function in Anderson-Fabry disease. Heart. 91 (2005) 533-534
18. Pochis W.T., Litzow J.T., King B.G., and Kenny D. Electrophysiologic findings in Fabry's disease with a short PR interval. Am J Cardiol. 74 (1994) 203-204
19. Shah J.S., Hughes D.A., Sachdev B., et al. Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am J Cardiol. 96 (2005) 842-846
20. Schiffmann R., Kopp J.B., Austin III H.A., et al. Enzyme replacement therapy in Fabry disease: A randomized controlled trial. JAMA 285 (2001) 2743-2749
21. Eng C.M., Guffon N., Wilcox W.R., et al., International Collaborative Fabry Disease Study Group. Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N Engl J Med. 345 (2001) 9-16
22. Banikazemi M., Bultas J., Waldek S., et al., Fabry Disease Clinical Trial Study Group. Agalsidase-beta therapy for advanced Fabry disease: A randomized trial. Ann Intern Med. 146 (2007) 77-86
23. Schiffmann R., Ries M., Timmons M., et al. Long-term therapy with agalsidase alfa for Fabry disease: Safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant. 21 (2006) 345-354
24. Germain D.P., Waldek S., Banikazemi M., et al. Sustained, long-term renalstabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol. 18 (2007) 1547-1557
25. Hughes D.A., Elliott P.M., Shah J., et al. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: A randomised, double-blind, placebocontrolled clinical trial of agalsidasealfa. Heart. 94 (2008) 153-158
26. Ries M., Clarke J.T., Whybra C., et al. Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics. 118 (2006) 924-932
27. Weidemann F., Breunig F., Beer M., et al. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: A prospective strain rate imaging study. Circulation. 108 (2003) 1299-1301
28. Spinelli L., Pisani A., Sabbatini M., et al. Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease. Clin Genet. 66 (2004) 158-165
29. Weidemann F., Niemann M., Breunig F., et al. Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: Evidence for a better outcome with early treatment. Circulation 119 (2009) 524-529
30. Pisani A., Spinelli L., Sabbatini M., et al. Enzyme replacement therapy in Fabry disease patients undergoing dialysis: Effects on quality of life and organ involvement. Am J Kidney Dis. 46 (2005) 120-127
31. Elliott P.M., Kindler H., Shah J.S., et al. Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A. Heart. 92 (2006) 357-360
32. Kalliokoski R.J., Kantola I., Kalliokoski K.K., et al. The effect of 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease. J Inherit Metab Dis. 29 (2006) 112-118
33. Whybra C., Mieback E., Mengel E., et al. A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease. Genet Med. 11 (2009) 441-449
34. Mehta A., Ricci R., Widmer U., et al. Fabry disease defined: Baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest. 34 (2004) 236-242
35. Beck M., Ricci R., Widmer U., et al. Fabry disease: Overall effects of agalsidase alfa treatment. Eur J Clin Invest. 34 (2004) 838-844
36. Sahn D.J., DeMaria A., Kisslo J., and Weyman A. Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements. Circulation 58 (1978) 1072-1083
37. Schiller N.B., Shah P.M., Crawford M., et al., American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr 2 (1989) 358-367
38. Devereux R.B. Detection of left ventricular hypertrophy by M-mode echocardiography. Anatomic validation, standardization, and comparison to other methods. Hypertension 9 (1987) II19-II26
39. de Simone G., Daniels S.R., Devereux R.B., et al. Left ventricular mass and body size in normotensive children and adults: Assessment of allometric relations and impact of overweight. J Am Coll Cardiol. 20 (1992) 1251-1260
40. Breunig F., Weidemann F., Strotmann J., et al. Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney Int. 69 (2006) 1216-1221
41. Beer M., Weidemann F., Breunig F., et al. Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy. Am J Cardiol. 97 (2006) 1515-1518
42. Vedder A.C., Breunig F., Donker-Koopman W.E., et al. Treatment of Fabry disease with different dosing regimens of agalsidase: Effects on antibody formation and GL-3. Mol Genet Metab. 94 (2008) 319-325
43. Elleder M., Bradová V., Smíd F., et al. Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy. Virchows Arch A Pathol Anat Histopathol. 417 (1990) 449-455
44. Sadick N., and Thomas L. Cardiovascular manifestations in Fabry disease: A clinical and echocardiographic study. Heart Lung Circ. 16 (2007) 200-206
45. Uchino M., Uyama E., Kawano H., et al. A histochemical and electron microscopic study of skeletal and cardiac muscle from a Fabry disease patient and carrier. Acta Neuropathol. 90 (1995) 334-338
46. Demuth K., and Germain D.P. Endothelial markers and homocysteine in patients with classic Fabry disease. Acta Paediatr Suppl. 91 (2002) 57-61